Namaxir (Methotrexate)

Methotrexate, the active ingredient in Namaxir, is an antimetabolite (folate antagonist) presented as a parenteral solution for injection use. It is used to treat rheumatoid arthritis, psoriasis and certain cancers in adults.

GNH USA supplies Namaxir as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methotrexate is employed across several disease families, primarily inflammatory and malignant conditions.

Rheumatoid arthritis: reduces joint inflammation and slows disease progression. Psoriasis: improves skin lesions and overall disease severity. Leukemia and lymphoma: interferes with malignant cell proliferation. Intraarticular treatment of joint inflammation: provides local immunosuppression and pain relief.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting - Fatigue or weakness - Mouth sores (stomatitis) - Decreased blood cell counts (anemia, leukopenia, thrombocytopenia) - Elevated liver enzymes - Hair thinning or loss

Serious or Rare Side Effects: - Severe liver toxicity or fibrosis - Pulmonary fibrosis or interstitial pneumonitis - Profound bone marrow suppression - Acute renal failure - Life‑threatening infections - Anaphylactic or severe hypersensitivity reactions

When using methotrexate, careful monitoring and specific precautions are essential.

Monitor liver function: perform regular liver enzyme tests. Assess renal function: adjust dose or avoid use in significant impairment. Check blood counts: frequent CBC monitoring for cytopenias. Avoid in pregnancy: drug is teratogenic and contraindicated (Category X). Use effective contraception: required during treatment and for several months after discontinuation. Store at ambient temperature: keep in original container, protect from moisture and light.

Methotrexate interacts with several medicines; some combinations must be avoided while others require close monitoring.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of renal toxicity. - Live vaccines: may cause severe infection due to immunosuppression. - Trimethoprim or other folate antagonists: additive toxicity.

Moderate Interactions (Monitor Closely): - Sulfonamide antibiotics: may enhance myelosuppression. - Azathioprine or other immunosuppressants: increased risk of bone‑marrow suppression. - Proton‑pump inhibitors: may alter methotrexate clearance. - Alcohol: can exacerbate liver toxicity.